INTRODUCTION {#S3}
============

Formation of the craniofacial complex is an intricate process of precisely timed events that occurs relatively early in vertebrate embryonic development. For example, in human embryonic development, the majority of the events that lead to the formation of the human face and skull occur during the first 10 weeks of gestation ([@R79]). Defects in the orchestration of these events result in several different congenital abnormalities, including orofacial clefting and craniosynostosis. Worldwide, orofacial clefting is one of the most common birth defects, affecting \~1 in 700 live births ([@R95]). The majority of those affected with these types of clefting do not have defects in other tissues or organ systems, and, thus, they are referred to as non-syndromic ([@R62]). While these birth defects are largely repairable through surgical means, the financial, sociological, and psychological effects have a much broader impact and represent a significant public health burden ([@R9]; [@R90]; [@R91], [@R92]). Screening, prevention, and non-surgical therapeutic options are thus highly desirable. The high heritability of such disorders suggests a major genetic component ([@R29], [@R30]); however, causative genetic changes have only been identified in a fraction of those affected ([@R3]; [@R82]).

In the past decade, numerous genome-wide association studies, copy number variant analyses, and whole-exome sequencing studies have sought to identify genetic sources of risk for craniofacial defects and normal human facial variation ([@R2]; [@R11]; [@R12]; [@R14]; [@R15]; [@R47]; [@R48]; [@R50]; [@R52], [@R53], [@R54]; [@R55], [@R56]; [@R63]; [@R96]; [@R97]). These studies identified common and rare variants associated with these phenotypes, but most are located in noncoding portions of the genome preventing functional interpretation and prioritization. Our genomes are littered with gene regulatory sequences, located primarily in intronic and intergenic sequences, which are active in a small number of tissues and/or developmental stages in humans ([@R40]). While the regulatory potential of the human genome is still not completely understood, defects in regulatory sequences can cause non-syndromic developmental defects in humans and mice ([@R49]; [@R66]; [@R77]; [@R89]). Of particular interest for craniofacial abnormalities, recurrent deletions of noncoding DNA near the *SOST* and *SOX9* genes have been implicated in Van Buchem disease and Pierre Robin sequence, respectively ([@R1]; [@R4]). These findings, coupled with the non-syndromic nature of most orofacial clefting and craniosynostosis cases ([@R45]; [@R83]), suggest defective gene regulatory sequences may underlie much of the incidence of craniofacial abnormalities.

Despite the common nature of such birth defects and defined windows of embryonic development in which they likely occur, mapping of chromatin states and identification of craniofacial-specific regulatory sequences have not been addressed by large functional genomics efforts such as Encyclopedia of DNA Elements (ENCODE) and Roadmap Epigenome ([@R40]). These large-scale projects have profiled chromatin states in cultured cell types derived *in vitro* from embryonic stem cells, fetal tissues from greater than 90 days of gestation, or adult post mortem samples, but they have not examined primary embryonic tissues. The embryonic period of human development, the first 8 weeks of gestation when much of craniofacial development occurs ([@R79]), has thus far been only characterized with a smaller number of functional genomics experiments in the developing limb and cortex and cultured cranial neural crest cells (CNCCs) ([@R68]). Particularly, comparisons of epigenomic signals in human and chimp CNCCs revealed differential utilization of regulatory sequences that may play roles in the normal formation and evolution of the human face. However, it is unclear how closely these culture models recapitulate early human craniofacial development.

The lack of primary, tissue-specific genomic annotations from this critical period of human development has impeded the identification of regulatory circuitry important for human craniofacial development, and it has prevented accurate interpretation of clinical genetic findings in patients with craniofacial disorders ([@R82]). Without sufficient biological context, prioritization and developing of hypotheses to test genetic associations with craniofacial abnormalities are hindered ([@R20]; [@R38]; [@R45]; [@R73]). Here, we present a comprehensive resource of functional genomics data and predicted chromatin states for critical stages of early human craniofacial development. We have profiled multiple biochemical marks of chromatin activity in developing human craniofacial tissue samples encompassing 4.5--8 post-conception weeks. We have comprehensively compared these data with publicly available functional genomics data from 127 epigenomes. We provide annotations consistent with large consortia efforts ([@R40]) in formats easily loadable into modern genome browsers to enable exploration by other researchers without large computational effort. In total, our analyses have identified thousands of previously unknown craniofacial enhancer sequences that will enable future experimental testing of enhancer-target gene interactions in developing craniofacial tissues. More importantly, this resource will facilitate future clinical interpretation of genetic variation in the context of congenital craniofacial defects that lack clear changes in the copy number or coding sequence of genes.

RESULTS {#S4}
=======

Profiling of Histone Modifications in Developing Human Embryonic Craniofacial Tissue {#S5}
------------------------------------------------------------------------------------

Chromatin immunoprecipitation of post-translational histone modifications coupled with next-generation sequencing (ChIP-seq) is a powerful method to identify active regulatory sequences in a global fashion from a wide variety of biological contexts ([@R40]). Many of the regulatory elements identified by this method are specific to the biological context queried ([@R88]; [@R99]) (i.e., tissue type or developmental stage), and they are enriched for genetic associations with disease in a relevant tissue (i.e., immune-related disorder associations in immune cell-specific enhancers) ([@R24]; [@R65]).

To identify regulatory sequences important for human craniofacial development, we utilized ChIP-seq of six post-translational histone modifications across multiple stages and multiple biological replicates of early human craniofacial development. We focused our efforts on histone modifications profiled by large consortia and strongly associated with multiple states of chromatin activity. We performed parallel ChIP-seq experiments on craniofacial tissues obtained from 17 individual human embryos spanning a critical window for the formation of the human orofacial apparatus ([Figure 1A](#F1){ref-type="fig"}). Specifically, we profiled marks ranging from those associated with repression (H3K27me3), promoter activation (H3K4me3), active transcription (H3K36me3), and various states of enhancer activation (H3K4me1, H3K4me2, and H3K27ac) ([Figure 1B](#F1){ref-type="fig"}) ([@R23]). We profiled at least three individual human embryonic craniofacial samples from each of four distinct Carnegie stages (CSs) (CS13, CS14, CS15, and CS17) encompassing 4.5 post-conception weeks (pcw) to 6 pcw ([@R79]). We also profiled single biological samples from CS20 (8-pcw) and 10-pcw embryos ([Figure 1C](#F1){ref-type="fig"}). We obtained over 5.3 billion ChIP-seq reads across a total of 106 datasets, with mean total reads and uniquely aligned reads per sample of 50.3 and 37.3 million, respectively, meeting guidelines proposed by ENCODE ([@R42]) ([Table S1](#SD2){ref-type="supplementary-material"}).

Overall the samples correlated well by mark and stage of development ([Figures 2A](#F2){ref-type="fig"}, [S1A, and S1B](#SD1){ref-type="supplementary-material"}). We uniformly processed these data to identify reproducibly enriched regions for each mark within each stage. The genomic features identified by each set of enriched regions closely mirror what has previously been reported for each of these post-translational marks ([Figures 2B](#F2){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}) ([@R23]; [@R99]). For example, we observed very strong enrichment of H3K4me3 at promoters of genes, and we identified a large number of intronic or intergenic regions enriched for H3K27ac. When we examined all the samples for a given CS, we identified thousands of enriched regions, at each stage for each mark, that were found in at least two biological replicates ([Figure 2C](#F2){ref-type="fig"}). Combined, these results indicated that our ChIP-seq data from primary human embryonic tissues were of high quality, reflected the previously described nature of these marks, and were likely to identify tissue-specific regulatory sequences.

Generation of Human Craniofacial Chromatin State Segmentations {#S6}
--------------------------------------------------------------

Defining enriched regions for a single histone modification such as H3K27ac has been utilized to identify active regulatory sequences from a variety of tissues, biological contexts, and different species ([@R18]; [@R19]; [@R64]; [@R75]; [@R86]). However, in the absence of H3K27ac, other marks can identify active regulatory sequences, and low levels of H3K27ac may be present at enhancers that are either about to become active or are no longer active ([@R8]; [@R17]; [@R39]). More advanced methods, such as using machine-learning techniques and integrating multiple chromatin signals from a single tissue, allow segmentation of the genome into a more complex array of biological states ([@R21]; [@R33]). These techniques can identify tissue-specific and disease-relevant regulatory information in heterogenous tissues that might not be readily apparent from gene expression data or analysis of promoter activation states ([@R23]; [@R34]).

To leverage such available data to identify regulatory information likely to be critical for craniofacial development, we processed our data in a uniform fashion to match those generated by Roadmap Epigenome ([@R40]). We first generated p value-based signals calculated on enrichment versus paired-input controls ([@R25]; [@R42]) for each of the six epigenomic marks we assayed. Then, using the same type of signals for 12 epigenomic marks for 127 tissues and cell types generated by Roadmap Epigenome, we imputed our data to create a uniform, directly comparable dataset of ChIP-seq signals ([@R22]). The imputed samples' signals correlated well with their primary signals and clustered generally by mark and biological function ([Figures 3A](#F3){ref-type="fig"}, [S1D, and S1E](#SD1){ref-type="supplementary-material"}). Using the imputed craniofacial data, we then segmented the genome using ChromHMM for each embryonic sample based on previously generated models of 15, 18, and 25 states of chromatin activity ([@R40]). We identified similar numbers and proportions of segments in each state in our tissues ([Figures 3B](#F3){ref-type="fig"} and [S2](#SD1){ref-type="supplementary-material"}). The 25-state model results showed the most similar trends across these measures, and they utilized all of the primary data generated in our study when compared to those previously generated by Roadmap Epigenome ([Figures 3C, 3D](#F3){ref-type="fig"}, and [S2](#SD1){ref-type="supplementary-material"}); therefore, we focused our downstream analyses on these segmentations.

Large active chromatin domains over the promoters of genes have been shown to identify critical regulators in developing tissues and differentiation models ([@R5]; [@R17]; [@R71]; [@R94]). Additionally, overlapping domains of activation and repressive-associated signals (H3K27ac, H3K4me3, and H3K27ame3) are potent identifiers of genes poised for activation in embryonic stem cells, or they display restricted domains or gradients of expression in heterogenous embryonic tissue samples ([@R5]; [@R17]; [@R71]; [@R70]). These bivalent signals were originally identified in embryonic stem cell cultures ([@R5]), but they were most recently reported in developing mouse pharyngeal arch tissue as important markers for the regulation of neural crest positional identity, and they were shown to play important roles in *Drosophila* development ([@R36]; [@R61]). These findings emphasize the biological importance of such chromatin states in developmental patterning, and they indicate that genes marked with such states are likely important for proper craniofacial development. These overlapping signals were annotated by a bivalent state in the 25-state model (23_PromBiv) and identified 957 genes with bivalent promoters. The genes identified by this bivalent state were strongly enriched for DNA-binding proteins, most significantly homeobox-containing transcription factors, and enriched for factors previously identified to play a role in embryonic cranial skeleton morphogenesis, such as the gene pair *DLX5* and *DLX6* ([Figures 4A](#F4){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}) ([@R76]).

In total, we identified 189 DNA-binding factors likely to be critical regulators of craniofacial development based on chromatin states ([Table S2](#SD3){ref-type="supplementary-material"}). Because of the important role ascribed to genes with bivalent status, as mentioned above, we sought to determine if any of the bivalent marks we identified were shared with previous data or specific for craniofacial tissue. To address this, we overlapped our bivalent state calls with the same bivalent state calls from all samples profiled by Roadmap Epigenome. Of the 957 genes identified above, only 7 genes were shown to have bivalent regions within 5 kb of their transcription start site ([Table S2](#SD3){ref-type="supplementary-material"}). In particular, we identified *EGR1* and *COX7A1* with a bivalent chromatin status not previously observed in Roadmap Epigenome. *EGR1* has been implicated in cranial cartilage development in zebrafish and expressed in early cartilage in mice ([@R60]), while *COX7A1* was shown to be differentially expressed in samples from patients with cleft lip only versus cleft lip and palate ([@R35]). When we analyzed genes reported to have bivalent status in mouse craniofacial tissues ([@R61]), 106 of 708 genes shared this status between human and mouse. Of these 106, 62 were DNA-binding proteins identified in our data, representing a significant enrichment in this class of protein among all bivalent genes (2.77-fold increase, Fisher p \< 0.0001; [Figure 4B](#F4){ref-type="fig"}; [Table S2](#SD3){ref-type="supplementary-material"}).

Lastly, to determine if this trend extends beyond chromatin marks to regions actively engaged by both activating and repressing complexes, we interrogated genes cobound in HUES64 human embryonic stem cells (ESCs) by BRD1, a component of the MOZ/MORF acetyltransferase complex, and RING1B, a component of Polycomb Repressive Complex 1 (PRC1) ([@R36]). We observed 134 genes of 609 cobound by these complexes had bivalent status in our data, the majority being DNA-binding factors (n = 92; 2.2-fold enrichment, Fisher p \< 0.0001; [Table S2](#SD3){ref-type="supplementary-material"}). Follow-up studies of these bivalent genes, especially the DNA-binding proteins, and the complexes that generate these states in a craniofacial context may reveal previously unknown roles in normal formation of the mammalian face and skull.

Identification of Craniofacial-Specific Enhancers and Craniofacial Super-enhancers {#S7}
----------------------------------------------------------------------------------

Having shown that our segmentations identify activation and/or poising of promoters important for craniofacial development, we next turned to regulatory portions of the genome. Using the 25-state segmentations, we reproducibly identified 75,928 segments in our craniofacial sample from at least one of six enhancer categories defined by Roadmap Epigenome (EnhA1, EnhA2, EnhAF, EnhW1, EnhW2, and EnhAc). To determine if our chromatin state segmentations identify bona fide craniofacial enhancers, we first compared craniofacial enhancer segments with H3K27ac ChIP-seq peak calls previously identified in cultured CNCCs ([@R68]). We found 30-fold (p \< 10^−4^) and 12-fold (p \< 10^−4^) enrichment of overlaps with the top 5,000 active CNCC enhancers and the top 1,000 human-biased CNCC enhancers, respectively ([Figures S4A and S4B](#SD1){ref-type="supplementary-material"}).

We then turned to a large catalog of experimentally validated developmental enhancers tested in mouse embryos and available in the Vista Enhancer Browser ([@R87]). We identified over 80% of all craniofacial-positive enhancers in this database (n = 170). Moreover, our enhancer annotations were significantly enriched for craniofacial enhancers versus those that lacked craniofacial activity (p = 3.28 × 10^−14^) ([Figures 5A, 5B](#F5){ref-type="fig"}, and [S4C](#SD1){ref-type="supplementary-material"}). While these results are encouraging, namely, that our data identified true craniofacial developmental enhancers, the chromatin state annotations alone do not reveal the specificity of individual regulatory regions nor do they identify target genes. To initially address this question, we quantitatively compared enhancer-associated H3K27ac signals at 425,380 enhancers from our craniofacial segmentations and 127 segmentations from Roadmap Epigenome. Both hierarchical clustering and principal-component analysis showed that our samples were well correlated with one another in this multi-tissue context ([Figures 5C](#F5){ref-type="fig"} and [S5](#SD1){ref-type="supplementary-material"}). They were most similar to ESCs and cell types derived from them (embryonic stem cell-derived; ESDR), but they were distinct from fetal and adult samples present in Roadmap Epigenome data, suggesting our annotations harbor regulatory information not previously annotated by Roadmap Epigenome. We also uniformly processed raw epigenomic data from human CNCCs ([@R68]) with our alignment, imputation, and segmentation pipeline. We found that the chromatin state segmentations for CNCC samples showed significant differences in the overall number and size of all chromatin states versus our data as well as Roadmap Epigenome ([Figures S2I and S2J](#SD1){ref-type="supplementary-material"}). Additionally, principal-component analysis of H3K27ac signal showed these cell types formed a cluster distinct from both the other ESDR types and our craniofacial samples ([Figure 5C](#F5){ref-type="fig"}). These results are likely due to differences in sequencing depth, the host of marks profiled, or distinct differences in the derivation of these cell types versus primary tissues that we cannot tease apart in this study. We therefore excluded chromatin state segmentations from these cell types from downstream multi-tissue comparisons.

Due to the isolated, tissue-specific nature of many craniofacial defects, we hypothesized that enhancers identified only in developing craniofacial tissues would be enriched near genes implicated in craniofacial abnormalities. To identify such enhancers in craniofacial tissue, we determined if any of our enhancer segments were ever annotated in Roadmap Epigenome. Overlaying our segmentations on those from 127 samples identified 6,651 enhancer segments specific for craniofacial development (8.7% of total craniofacial enhancer segments) ([Table S1](#SD2){ref-type="supplementary-material"}; [Figure S6](#SD1){ref-type="supplementary-material"}). To determine if these sites are relevant for craniofacial development or represent spurious segmentations in our data, we analyzed sequence content of these regions and functional enrichments of genes potentially regulated by these regions. When we assessed the craniofacial-specific enhancers for enrichment of transcription factor-binding sites, we identified motifs matching those of *TWIST2*, *LMX1B*, *SIX1*, *NKX6.1*, multiple members of the *LHX* and *HOX* families, and *TCF12*, all of which have been implicated in craniofacial and skeletal development ([@R10]; [@R13]; [@R26]; [@R41]; [@R57]; [@R80]; [@R98]; [Figure 5D](#F5){ref-type="fig"}; [Table S3](#SD4){ref-type="supplementary-material"}). Utilizing the Genomic Regions Enrichment of Annotations Tool (GREAT) ([@R59]), we found significant enrichment of craniofacial-specific enhancers assigned to genes associated with craniofacial abnormalities, such as cleft palate in both humans and mice ([Figure 5E](#F5){ref-type="fig"}). Interestingly, we also identified more general categories of enrichment among the putative gene targets, including general transcriptional activators ([Table S3](#SD4){ref-type="supplementary-material"}). When we interrogated this list of transcription factors for tissue-specific biology ([@R27]), we found significant enrichment for phenotypes related to craniofacial and appendicular skeleton ([Figure 5F](#F5){ref-type="fig"}).

The above analyses focused on the annotation and activation state of individual genome segments. However, these enhancers likely do not operate in isolation, and clusters of enhancers activated in concert have been shown to be powerful regulators of important genes for a given tissue or cell type ([@R94]). To identify such enhancer clusters, we applied the rank order of super enhancers (ROSE) ([@R94]) algorithm for identifying super-enhancers as well as a sliding window approach to detect enrichment of craniofacial enhancer states relative to both randomly chosen sequences as well as those identified by Roadmap Epigenome. We identified 581 regions across the genome that demonstrated enrichment for craniofacial enhancers or identified as a super-enhancer region ([Table S4](#SD5){ref-type="supplementary-material"}). These windows had an average size of \~400 kb but ranged up to 2 Mb in length. In many cell types, these clusters of enhancers are embedded in the genome both surrounding and within the introns of their likely tissue-specific target ([@R32]). Indeed, most of the super-enhancer regions and enhancer-enriched windows we identified contained multiple genes (mean of 4.7 genes per window) and were enriched for developmental genes, including multiple *FZD*, *WNT*, *ALX*, *DLX*, and *TBX* family members ([Table S4](#SD5){ref-type="supplementary-material"}). These super-enhancer regions encompass virtually all of the same bivalent domains identified above (951 of 957), suggesting they have complex, concerted activation by regulatory elements throughout the developing craniofacial complex.

The most significantly enriched super-enhancer region based on both fractions of bases annotated as an enhancer state and H3K27ac signals across all craniofacial samples encompassed the *PRDM16* gene. The promoter of this gene is identified as a bivalent region, and both the large noncoding region upstream and large intronic sequences are littered with strongly active enhancers ([Figure S7](#SD1){ref-type="supplementary-material"}). Work in mice has identified point mutations in *Prdm16* that give rise to cleft palate, but a role for this gene in human craniofacial abnormalities has not been concretely identified ([@R7]). The PRDM16 protein has been implicated in the methylation of H3K9, suggesting this protein could also be involved in maintaining bivalent states described above ([@R67]). The strong epigenomic signals we identified in primary tissue surrounding this gene, its bivalent promoter, and reported histone modification activity suggest this gene may contribute to the regulation of many genes in craniofacial development.

Enrichment of Orofacial Clefting and Facial Variation Genetic Associations in Craniofacial Enhancers {#S8}
----------------------------------------------------------------------------------------------------

The results above suggest that many of the craniofacial enhancers we identified are likely to play a direct role in the patterning of bones of the face, jaws, and portions of the skull. However, it is unclear whether they are directly involved in human craniofacial abnormalities. To begin to explore whether the enhancers we identified play a role in craniofacial abnormalities, we first turned to regulatory regions previously identified as causative in two distinct craniofacial syndromes. Van Buchem disease is a rare disorder characterized by bone overgrowth in the jaws and skull ([@R85]). A large noncoding deletion was identified in a Dutch family between the *MEOX1* and *SOST* genes ([@R1]). All of our chromatin state segmentations identified several strong enhancer states in this window, including at least one region previously tested in the developing mouse based on conservation ([@R51]). However, we also identified a craniofacial-specific enhancer state overlapping a deeply conserved sequence (ERC7) as well as enhancers that lacked significant conservation in this interval that could play a role in Van Buchem disease ([Figure 6A](#F6){ref-type="fig"}). We then turned to Pierre Robin sequence (PRS), a syndrome characterized by a reduced lower jaw, misplacement of the tongue, and frequent occurrence of cleft palate ([@R81]). Genetic mapping in several multi-generational families affected by PRS identified recurrent deletions and translocations in a 2.46-Mb noncoding region between *KCNJ2* and *SOX9* ([@R4]; [@R28]). Our data identified numerous shared and craniofacial-specific enhancers throughout this region ([Figure 6B](#F6){ref-type="fig"}). Most importantly, for two families with overlapping genetic changes, we identified craniofacial-specific enhancers within this region, including one overlapping the 200-bp sequence hypothesized to be causative in at least one of these families (F1 and F2 from [@R4]). Our craniofacial-specific segmentations also identified at least two other highly conserved regions upstream of the originally tested sequence, one of which showed craniofacial regulatory capacity ([Figure 6C](#F6){ref-type="fig"}) ([@R28]).

The first genome-wide association for non-syndromic cleft lip and/or palate was identified at the 8q24 locus encompassing a 640-kb noncoding region downstream of the *MYC* gene ([Figure S8A](#SD1){ref-type="supplementary-material"}) ([@R6]). This region has a very significant impact on nonsyndromic cleft lip and/or palate (NSCLP) risk, the rs987525 SNP in this region yielding odds ratios ranging from 2.07 to 4.68 ([@R52]). While we did not annotate an enhancer directly overlapping this SNP position, we did identify a craniofacial enhancer state in all of our samples \~2 kb downstream ([Figure S8B](#SD1){ref-type="supplementary-material"}). Additionally, this large noncoding region has been studied with a number of mouse deletion lines ([@R84]). Overlapping deletions revealed a 280-kb region dubbed a medionasal enhancer region (MNE) and a 106-kb nasal epithelial enhancer region (NEE) in the developing mouse. Deletion of the MNE resulted in lower *Myc* expression in multiple developing mouse tissues and an elevated incidence of cleft lip and palate. Inspection of these orthologous regions in the human genome revealed multiple craniofacial enhancers active across multiple states, several of which were more strongly active later in development. In particular, the only strong enhancer states annotated in each region were located near the center of both deletion intervals ([Figures S8C and S8D](#SD1){ref-type="supplementary-material"}). Our data support the findings reported for this region in the mouse for orofacial clefting, but our annotations narrow the search for causative regulatory regions within these still relatively large regions to less than 5 kb.

We next turned to the most recent genome-wide associations from several comprehensive meta-analyses focused on orofacial clefting ([@R47]; [@R54]; [@R96]). We overlaid associations from these studies along with SNPs in strong linkage disequilibrium with each of the segmentation maps from our data, as well as data from Roadmap Epigenome, and we assessed enrichment using genomic regulatory elements and GWAS overlap algorithm (GREGOR) ([@R78]). As a control, we also interrogated associations for Crohn's disease for enrichment in our enhancers ([@R93]). We did not observe any significant enrichment of Crohn's-associated SNPs in our craniofacial segmentations. However, we did observe strong enrichment among enhancers identified in immune-related cell types and tissues. This result agreed with previous findings, and it validated our approach for assessing enrichment of genetic associations ([Figure S9A](#SD1){ref-type="supplementary-material"}) ([@R44]). When we analyzed associations for orofacial clefting, we observed significant enrichment of SNPs reported from all three studies in our craniofacial enhancers. The most significant findings in our data were consistently observed from SNPs reported by [@R96] ([Figures 7A](#F7){ref-type="fig"}, [S9B, and S9C](#SD1){ref-type="supplementary-material"}). However, only the credible SNPs for 24 regions based on imputation of genotyping data showed enrichment in our much smaller number of craniofacial-specific enhancers relative to total enhancers in each segmentation ([Figure S9C](#SD1){ref-type="supplementary-material"}) ([@R54]).

Interestingly, for all three orofacial clefting studies, enhancer segmentations from our early samples (CS13--CS15) showed the most significant enrichments. These results suggested defective patterning events during early embryonic development drive these abnormalities. For example, we identified a discrete enhancer state in the noncoding region between *IRF6* and *DIEXF* that contains a tag SNP previously associated with non-syndromic cleft lip and palate ([@R100]; [Figure 7B](#F7){ref-type="fig"}). This particular enhancer region has been reported to influence *IRF6* expression, and it is potentially causative for orofacial clefting, particularly cases of cleft lip without cleft palate ([@R72]). In our data, we observe an enhancer state from CS13 to CS15, but not in samples from CS17 and beyond. This finding would agree with the stronger genetic associations for this region with cleft lip alone as the external features of the human face, particularly the lip, close earlier in human development than the palate ([@R79]). Our data may also be informative for other large loci previously implicated in orofacial clefting. Inspection of several of these loci, including 1p22, 1p36, 10q25, 15q13, 17q22, and 20q12, identified craniofacial enhancer states near tag SNPs previously reported ([@R46], [@R47]; [@R54]; [@R56]; [@R96]). However, our annotations also identified regulatory regions some distance away, near bivalent genes or the proposed target gene in these intervals that may also be important and potentially harbor rare variation not detectable in a genome-wide association study (GWAS) ([Figures S10--S17](#SD1){ref-type="supplementary-material"}).

Finally, while the regulatory regions identified here were enriched for associations with craniofacial abnormalities, it is unclear if these regions were also informative for understating the wide variety of craniofacial shapes and appearances among humans. Recent GWAS searching for genetic associations with variability in multiple measures of facial shape identified 38 loci in those of European ancestry ([@R14]). These loci were reported to be enriched near regions with elevated H3K27ac signals in cultured human CNCCs. Indeed, when we interrogated our enhancer segmentations with the craniofacial measure SNPs using the same approach as above for orofacial clefting SNPs, we also observed significant enrichment ([Figure 7C](#F7){ref-type="fig"}). However, unlike the orofacial clefting associations, the craniofacial measure associations were most strongly enriched in enhancers from later stages of our cohort, particularly CS17 and beyond. This would suggest regulatory events in late embryonic and early fetal development contribute to human facial variation. In summary, these results demonstrate that our chromatin state maps are enriched for genetic information necessary for normal craniofacial development and will be extremely useful in identifying and prioritizing causative variation in patients affected by craniofacial abnormalities as well as understanding normal human facial variation.

DISCUSSION {#S9}
==========

Recent large consortia efforts to identify the genetics of common disease have gained traction utilizing tissue-specific annotations of the genome to identify potential regulatory regions and overlying genetic associations ([@R24]; [@R65]). Such genetic association data exist for craniofacial abnormalities, but the lack of craniofacial-specific annotations of regulatory function has prevented systematic identification of causal genetic changes. We have addressed this need by generating an extensive resource of functional genomics data obtained directly from human craniofacial tissues during important stages of formation of the orofacial apparatus. We have uniformly processed our data to allow integration of these data with similarly generated signals from a variety of human tissues and developmental stages. These analyses have allowed us to generate craniofacial-specific annotations of chromatin states across the human genome. These chromatin state segmentations reveal tens of thousands of regions with potential gene regulatory activity in craniofacial development.

Our analyses identified a significant proportion of previously known genes and loci important for normal craniofacial development in mice and humans. Specifically, our bivalent promoter and super-enhancer annotations identified key developmental transcription factors as well as large noncoding regions that showed extensive activation during early craniofacial development. The bivalent promoters most likely reflect two possibilities: genes that have restricted patterns of expression in the developing craniofacial tissues or poised genes that can be rapidly activated during development. Due to the heterogeneous nature of the tissue and processing in bulk, it is difficult to determine between these two possibilities. Further efforts using gene expression data, such as single-cell RNA-seq, a battery of *in situ* hybridizations, or sequential ChIP-seq experiments, will be required to elucidate the exact nature of chromatin at these genes and determine the contributions that genes identified here make to normal craniofacial development.

The systematic localization of SNPs associated with orofacial clefting and normal facial variation in our craniofacial enhancer annotations agrees with previous work from other human fetal tissues ([@R58]), but it extends this to a tissue/disease-specific context. Specifically, our results support the idea that common variants associated with risk for orofacial clefting, particularly in the case of the cleft lip association for an enhancer of *IRF6*, manifest early in embryonic development, likely in the first 3--5 weeks of gestation. This is in contrast to our results from analyzing craniofacial measure associations. These genetic associations were most strongly enriched in samples from 6 to 9 weeks of gestation, implicating fine-tuning of craniofacial appearance after most of the external features have been established.

Related to this idea, we processed previously published epigenomic data from cultured CNCCs ([@R68]). We observed significant overlaps between our craniofacial enhancer segments and CNCC H3K27ac peak calls as well as human-biased CNCC H3K27ac regions. These findings suggest that we have identified regulatory information that is important for the evolution of the human face and that culture models may reflect some of the regulatory architecture of primary human craniofacial development. However, upon further interrogation with our uniform pipeline, we found that the chromatin state segmentations for CNCC samples showed distinct differences in the overall number and size of all chromatin states versus our data as well as Roadmap Epigenome ([Figures S2I and S2J](#SD1){ref-type="supplementary-material"}). This is potentially due to differences in depth of sequencing, the collection of histone modifications profiled, or the derivation of these cell types versus normal embryonic development. On this last point, enrichment of craniofacial measure associations in enhancers at later stages of development would indicate that the CNCC system generates cells much more differentiated or derived than previously appreciated. This also challenges the previous interpretation that normal variation of the human face is influenced strongly by early embryonic cell types ([@R14]). Instead, our findings support the idea that these variations result from fine-tuning of the structures after the basic structure of the face has been patterned. Further global characterization of culture models of early craniofacial development, using our epigenomic data as a guide, will be necessary to generate conditions that yield differentiation schemes more reflective of the primary tissue environment. Such systems will be necessary to perform systematic genome modification experiments (deletions, rearrangements, etc.) targeting the regions we have identified to understand their function.

Our data represent one of the most comprehensive epigenetic profiles of primary tissue from the embryonic period of human development. Over 6,000 of the enhancer segments we defined are newly identified, and, as we have shown, they reveal regions with functional contribution to genetic variation associated with disease and facial shape. These regions are strongly enriched near genes implicated in craniofacial development, and they would have remained unknown to craniofacial researchers relying solely on the current state of genome annotations. Indeed, recent targeted sequencing of GWAS intervals at 13 loci in patients affected by craniofacial abnormalities likely included many inert regions but also excluded important craniofacial regulatory regions due to the lack of appropriate chromatin state annotations ([@R46]) (top black bars in [Figures S6B, S10, S12, S13, S14, S16, and S17](#SD1){ref-type="supplementary-material"}). These results illuminate that our current understanding of the regulatory information our genomes encode is incomplete and reinforce the need for more, higher-resolution, tissue-specific profiling of multiple epigenomic marks to yield comparable chromatin state annotations from primary tissues.

We provide all our craniofacial functional genomics data and resulting chromatin state segmentations totaling 1,978 tracks in several standard formats as well as a complete catalog of tracks that can be easily loaded into many modern genome browsers. Our data are listed in the public track hub section of the University of California, Santa Cruz (UCSC) Genome Browser as well as the Track Hub Registry (<http://trackhubregistry.org/>). Additionally, we have preloaded our annotations and chromatin signals at multiple genes implicated in craniofacial abnormalities in the UCSC Genome Browser that can be opened with a single click on links found at our laboratory website (<https://cotney.research.uchc.edu/data/>). In total, this resource will allow the craniofacial community and other developmental biologists to develop hypotheses that are rooted in human craniofacial biology instead of using chromatin state annotations from other tissues not directly related to the tissue of interest. This work brings the craniofacial research world firmly into the functional genomics era, advances our understanding of these disorders from a regulatory perspective, and provides tools for clinicians and researchers seeking to diagnose patients utilizing whole-genome sequencing.

EXPERIMENTAL PROCEDURES {#S10}
=======================

Further details and an outline of resources used in this work can be found in the [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.

Tissue Collection and Fixation {#S11}
------------------------------

Use of human fetal tissue was reviewd and approved by the Human Subjects Protection Program at UConn Health (UCHC 710-2-13-14-03). Human embryonic craniofacial tissue was collected, staged, and provided by the Joint MRC/ Wellcome Trust Human Developmental Biology Resource ([www.hdbr.org](www.hdbr.org)). Information describing the developmental stage, termination method, collection site, and karyotype of each embryo is found in [Table S1](#SD2){ref-type="supplementary-material"}. Tissues were flash frozen upon collection and stored at −80°C. Fixation for ChIP-seq was performed as described in [@R16]. Fixed tissue pellets were stored at −80°C until batch processing for ChIP.

Quantification and Statistical Analysis {#S12}
---------------------------------------

### ChIP-Seq {#S13}

Fixed tissue pellets were processed for ChIP as previously described ([@R16]). Antibodies used in this study were as follows: anti-H3K27ac (ab4729, Abcam), anti-H3K4me1 (ab8895, Abcam), anti-H3K4me2 (ab7766, Abcam), anti-H3K4me3 (ab8580, Abcam), anti-H3K27me3 (07-449, EMD Millipore), and anti-H3K36me3 (ab9050, Abcam). ChIP-seq libraries were quantified by qPCR (NEBNext Library Quant Kit for Illumina), multiplexed, and sequenced for 75 cycles across multiple flow cells on an Illumina NextSeq 500 instrument.

### Primary ChIP-Seq Data Analysis {#S14}

ChIP-seq reads were aligned to the human genome (hg19) using Bowtie2 (version \[v.\] 2.2.5) ([@R43]). Fragment sizes of each library were estimated using PhantomPeakQualTools (v.1.14) ([@R42]). Histone modification-enriched regions were identified and annotated using Hypergeometric Optimization of Motif Enrichment (HOMER, v.4.8.3) ([@R31]). Reproducibly enriched regions were determined by creating a union of all enriched regions for a respective histone modification from all replicates of a single CS and filtering for regions identified in at least two biological replicates using BEDtools (v.2.25.0) ([@R69]). We then generated p value-based signal tracks relative to appropriate input controls based on estimated library fragment size using MACS2 (2.1.1.20160309) ([@R25]). All signal and enriched region files were converted for display in the UCSC Genome Browser using the Kent Source Tools (v.329) ([@R37]). Correlations of ChIP-seq signals and principal-component analysis across samples and markfs were calculated in non-overlapping 10-kb windows using deepTools2 (v.2.5.0.1) ([@R74]).

DATA AND SOFTWARE AVAILABILITY {#S15}
------------------------------

The accession number for the ChIP-seq signals, peak calls, and chromatin state segmentations reported in this paper is GEO: GSE97752.

All data can be visualized in the UCSC Genome Browser using publicly available track hub functionality. Hub files and interesting browser examples can be found on our website (<https://cotney.research.uchc.edu/data/>).

All generic scripts used in processing ChIP-seq and generating chromatin states are available on GitHub (<https://github.com/cotneylab/ChIP-Seq>).

Supplementary Material {#S17}
======================
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![Overview of Epigenomic Profiling of Early Human Craniofacial Development\
(A) Stages and craniofacial tissues (orange shading) of human embryonic development sampled in this study, indicated as individual Carnegie stages (CSs) or approximate post-conception weeks (pcw). Voids or cleavages in the embryo are indicated by black-shaded regions and do not indicate deformities.\
(B) Six post-translational modifications of histones were profiled in parallel from individual human embryos via ChIP-seq.\
(C) Signals from primary ChIP-seq data were imputed using ChromImpute ([@R22]) to match the 12 epigenomic signals profiled by Roadmap Epigenome ([@R40]). Asterisks indicate signals containing only imputed data. These imputed datasets were then used to predict chromatin states using a Hidden Markov Model approach (ChromHMM) ([@R21]) across the genome for each craniofacial tissue sample. These chromatin states were then used for downstream functional analyses to determine relevance for craniofacial biology and disease. (See also [Figure S1](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.)](nihms965685f1){#F1}

![Histone Modification Profiles in Human Craniofacial Development\
(A) Heatmap and hierarchical clustering of pairwise Pearson correlations for non-overlapping 10-kb bins across the human genome for 114 individual histone modification profiles from human craniofacial tissues. Relatedness of epigenomic profiles by sample is indicated by dendrogram along the vertical axes of the heatmap. Darker orange indicates positive correlation between datasets.\
(B) Genomic feature annotations identified by peak calls from six histone modification profiles from the same tissue sample plotted as cumulative percentage of total peaks. Peak enrichments and genomic annotations were performed using HOMER ([@R31]).\
(C) Histone modification peaks identified in at least two separate tissue samples from the same developmental stage and annotated into three broad categories: promoter (2 kb upstream of transcription start site \[TSS\]), exons, and all other intronic or intergenic locations. (See also [Figure S1](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.)](nihms965685f2){#F2}

![Imputation of Craniofacial Epigenomic Signals and Chromatin State Segmentation\
(A) Principal-component analysis projection of first two component dimensions for 252 imputed and 114 primary epigenomic profiles for human craniofacial samples across non-overlapping 10-kb bins. Samples are color coded by epigenomic mark and shapes indicate primary versus imputed data types. Samples generally cluster into three broad categories of activity: repression, regulatory element activation, and transcription regulation. (See also [Figures S1D and S1E](#SD1){ref-type="supplementary-material"}.)\
(B) Numbers of individual chromatin state segments identified by each of the color-coded 25 states of chromatin activity based on imputed epigenomic signals for each of the 21 tissue samples profiled.\
(C) Comparison of cumulative percentage of each chromatin state between craniofacial samples profiled here and 127 segmentations generated by Roadmap Epigenome ([@R40]).\
(D) Mean numbers of segments annotated in each of the 25 states across 21 craniofacial samples (orange) and 127 Roadmap Epigenomes (gray). Error bars represent SD. Overall chromatin state segmentation in craniofacial samples identifies similar numbers and percentages of each of 25 states published by Roadmap Epigenome ([@R40]). (See also [Figure S2](#SD1){ref-type="supplementary-material"}.)](nihms965685f3){#F3}

![Large Bivalent Domains at Gene Pair *DLX5* and *DLX6*\
(A) UCSC Genome Browser shot of locus encompassing the *DLX5/DLX6* locus. At top are chromatin state segmentations for all tissue samples. Purple states indicate bivalent regions. Imputed signals and peak calls for representative samples from each stage and for each indicated histone mark are shown below.\
(B) DNA-binding proteins identified as having a bivalent promoter state in human embryonic craniofacial development. Genes in bold were also identified as having bivalent status during early mouse craniofacial development ([@R61]). (See also [Figure S3](#SD1){ref-type="supplementary-material"} and [Table S2](#SD2){ref-type="supplementary-material"}.)](nihms965685f4){#F4}

![Chromatin State Segmentations Identify Craniofacial-Specific Regulatory Sequences\
(A) Percentage of *in vivo*-validated embryonic enhancers with (orange) or without (gray) craniofacial activity from the Vista Enhancer Browser ([@R87]) identified by craniofacial chromatin segments annotated as enhancer states. Significance was determined by Fisher's exact test.\
(B) Selected validated enhancers with craniofacial activity identified by this study from the Vista Enhancer Browser. (See also [Figure S4](#SD1){ref-type="supplementary-material"}.)\
(C) Principal-component analysis projection of second and third component dimensions for 149 H3K27ac profiles at 425,568 regions annotated as enhancer segments in any of the samples profiled here or by Roadmap Epigenome. Samples are color coded by group annotations assigned by Roadmap Epigenome or craniofacial samples from this study. Percentages of variance across samples explained by each component are indicated along each axis. (See also [Figure S5](#SD1){ref-type="supplementary-material"}.)\
(D) Transcription factor position weight matrices identified by HOMER ([@R31]) as enriched in craniofacial-specific enhancer segments. (See also [Table S3](#SD2){ref-type="supplementary-material"}.)\
(E) Significant enrichments of human disease phenotypes for genes assigned to craniofacial-specific enhancer segments, as reported by GREAT ([@R59]). (See also [Figures S6 and S7](#SD1){ref-type="supplementary-material"}.)\
(F) Enrichment of anatomical expression of transcription factors identified as potentially regulated by craniofacial-specific enhancer segments, as reported by GeneORGANizer ([@R27]). Heat indicates fold enrichment of expression in individual anatomical region or organ. Craniofacial and appendicular skeleton showed the most significant enrichments.](nihms965685f5){#F5}

![Human Craniofacial Enhancers Identify Regions Important for Van Buchem Disease and Pierre Robin Sequence\
(A) UCSC Genome Browser shot of locus encompassing the large noncoding region flanked by *MEOX1* and *SOST.* Region deleted in a Dutch family affected by Van Buchem disease is indicated by the black bar. Conserved regions (ERC) tested by [@R51] are indicated above conservation tracks. Craniofacial-specific enhancer near ERC7 is indicated in orange. Additional regions annotated with strong craniofacial enhancer states but with relatively low conservation in the Van Buchem interval are indicated by purple box.\
(B) UCSC Genome Browser shot of locus encompassing the large noncoding region flanked by *KCNJ2* and *SOX9* and associated with Pierre Robin sequence (PRS). Black bars indicate intervals altered in PRS families as previously reported by [@R4]. Region encompassing the F2 mutation is highlighted in the following panel.\
(C) Enlarged view of F1 deletion region and conserved noncoding element affected by F2 mutation (HCNE-F2). Craniofacial-specific enhancer regions are indicated by orange bars. A portion of one of these regions was tested in the Vista Enhancer Browser (mm628). Inset panel shows enhancer activity of mm628 in embryonic day (E) 11.5 mouse embryos from the Vista Enhancer Browser. (See also [Figures S8 and S10--S17](#SD1){ref-type="supplementary-material"}.)](nihms965685f6){#F6}

![Enrichment of Orofacial Clefting and Cranio-facial Measure Associations in Craniofacial Enhancers\
(A) Enrichment of orofacial cleft GWAS tag SNPs identified by [@R96] in enhancer segmentations was assessed using GREGOR ([@R78]). Orange circles indicate craniofacial enhancer annotations identified by a 25-state chromatin model from this study, while gray circles indicate those previously published by Roadmap Epigenome ([@R40]).\
(B) Enhancer state analysis permits placement of a potentially causative allele for non-syndromic CL/P (rs642961) ([@R72]) within a predicted early development enhancer state. This enhancer state is located between *IRF6* and *DIEXF* and may influence expression of *IRF6*. (See also [Table S4](#SD2){ref-type="supplementary-material"}.)\
(C) Same analysis as in (A) using GWAS tag SNPs reported for craniofacial measures by [@R14]. (See also [Figure S9](#SD1){ref-type="supplementary-material"}.)](nihms965685f7){#F7}

###### Highlights

-   Global profiling of histone modifications across early human craniofacial development

-   Chromatin state segmentation reveals enhancers with craniofacial-specific activation

-   Early craniofacial enhancers enriched with genetic associations for orofacial clefting

-   Late craniofacial enhancers enriched with genetic associations for normal facial shape
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